

FULL TEXT LINKS

[Review](#) > [J Neuroimmunol](#). 2021 Dec 15;361:577758. doi: 10.1016/j.jneuroim.2021.577758.

Epub 2021 Oct 28.

The involvement of JAK/STAT signaling pathway in the treatment of Parkinson's disease

Naser-Aldin Lashgari ¹, Nazanin Momeni Roudsari ¹, Saeideh Momtaz ², Thozhukat Sathyapalan ³, Amir Hossein Abdolghaffari ⁴, Amirhossein Sahebkar ⁵

Affiliations

PMID: 34739911 DOI: [10.1016/j.jneuroim.2021.577758](https://doi.org/10.1016/j.jneuroim.2021.577758)

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder in which inflammation and oxidative stress play key etiopathological role. The pathology of PD brain is characterized by inclusions of aggregated α -synuclein (α -SYN) in the cytoplasmic region of neurons. Clinical evidence suggests that stimulation of pro-inflammatory cytokines leads to neuroinflammation in the affected brain regions. Upon neuroinflammation, the Janus Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) signaling pathway, and other transcription factors such as nuclear factor κ B (NF- κ B), NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3), mammalian target of rapamycin (mTOR), and toll-like receptors (TLRs) are upregulated and induce the microglial activation, contributing to PD via dopaminergic neuron autophagy. Aberrant activation or phosphorylation of the components of JAK/STAT signaling pathway has been implicated in increased transcription of the inflammation-associated genes and many neurodegenerative disorders such as PD. Interferon gamma (IFN- γ), and interleukine (IL)-6 are two of the most potent activators of the JAK/STAT pathway, and it was shown to be elevated in PD. Stimulation of microglial cell with aggregated α -SYN results in production of nitric oxide (NO), tumor necrosis factor (TNF)- α , and IL-1 β in PD. Dysregulation of the JAK/STAT in PD and its involvement in various inflammatory pathways make it a promising PD therapy approach. So far, a variety of synthetic or natural small-molecule JAK inhibitors (Jak inhibitors) have been found promising in managing a spectrum of ailments, many of which are in preclinical research or clinical trials. Herein, we provided a perspective on the function of the JAK/STAT signaling pathway in PD progression and gathered data that describe the rationale evidence on the potential application of Jak inhibitors to improve neuroinflammation in PD.

Keywords: JAK/STAT; Jak inhibitors; Neuroinflammation; Parkinson's disease.

Copyright © 2021 Elsevier B.V. All rights reserved.

Related information

[MedGen](#)

LinkOut – more resources

Full Text Sources

[ClinicalKey](#)[Elsevier Science](#)

Medical

[Genetic Alliance](#)

[MedlinePlus Health Information](#)

Miscellaneous

[NCI CPTAC Assay Portal](#)